| 常 青,钱嘉琳,张岩巍.晚期非鳞非小细胞肺癌患者化疗疗效、缓解深度与无进展生存期的相关性[J].肿瘤学杂志,2019,25(9):793-797. |
| 晚期非鳞非小细胞肺癌患者化疗疗效、缓解深度与无进展生存期的相关性 |
| Correlation of Survival with Therapy Effect，Depth of Response in Patients with Advanced No-Squamous Non-Small Cell Lung Cancer Following Chemotherapy |
| 投稿时间：2018-10-09 |
| DOI：10.11735/j.issn.1671-170X.2019.09.B006 |
|
 |
| 中文关键词: 非小细胞肺癌 化疗 缓解深度 无进展生存期 |
| 英文关键词:non-small cell lung cancer chemotherapy depth of response progression free survival |
| 基金项目:上海市科学技术委员会西医引导类项目（16411964700； 18411968500） |
|
| 摘要点击次数: 1940 |
| 全文下载次数: 481 |
| 中文摘要: |
| 摘 要：［目的］ 探讨晚期非鳞非小细胞肺癌（NS-NSCLC)患者紫杉醇卡铂联合贝伐珠单抗（TCBev）方案化疗后治疗疗效、缓解深度（DpR）、肿瘤缩小速度分别与生存获益的关系。［方法］ 回顾性分析80例一线接受TCBev方案化疗的晚期NS-NSCLC患者的临床资料。治疗疗效按实体肿瘤疗效评价标准（RECIST）进行分类；按30%和60%的DpR将患者分为3个亚组；按中位DpR达到最大值时间（TTMD）将患者分为2个亚组。 ［结果］ 38例（47.5%）患者达PR，37例（46.2%）SD，5例（6.3%）治疗后病灶增大。PR比SD患者的无进展生存期（PFS）时间长（9.6个月vs 6.9个月，P＜0.001）；DpR越大，PFS时间越长（10.6个月vs 8.2 vs 6.4个月，P＜0.001）；快速缩小（TTMD≤4.07个月）和缓慢缩小的PFS无统计学差异（6.9个月vs 8.2个月，P=0.524）。［结论］ 晚期NS-NSCLC患者接受TCBev方案化疗后，出现PR或者肿瘤缩小越明显时，其PFS时间相对越长，然而，肿瘤缩小的速度与PFS无明显相关性。 |
| 英文摘要: |
| Abstract：［Objective］ To investigate the relationship of survival with therapy effect，depth of response(DpR) and tumor shrinkage rate in patients with advanced no-squamous non-small cell lung cancer(NS-NSCLC) following chemotherapy. ［Methods］ The clinical data of 80 advanced NS-NSCLC patients who received paclitaxel carboplatin combined with bevacizumab(TCBev) regimen as first-line chemotherapy were retrospectively analyzed. The therapeutic effect was assessed according to the response evaluation criteria in solid tumor(RECIST). Patients were divided into three subgroups according to 30% and 60% DpR. Patients were divided into two subgroups according to median time to max DpR(TTMD). ［Results］ Among 80 patients，there were 38 cases(47.5%) with PR，37(46.2%) with SD，and 5(6.3%) with enlarged target lesions. The progression free survival(PFS) of PR patients was longer than that of SD patients(9.6 months vs 6.9 months，P<0.001). Patients with longer DpR had longer PFS(10.6 months vs 8.2 vs 6.4 months，P<0.001). There was no significant difference in PFS between the rapid reduction(TTMD ≤ 4.07 months) and slow reduction subgroups(6.9 months vs 8.2 months，P=0.524). ［Conclusion］ For patients with advanced NS-NSCLC treated with TCBev，the PFS is relatively long when therapy effect achieves PR or significant DpR，however，there is no significant correlation between tumor shrinkage rate and PFS. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |